Liver Cancer | Tumor

Derazantinib May Demonstrate Promising Disease Control in Some Patients With Cholangiocarcinoma

May 7th 2021, 9:00pm


Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.

FDA Panel Votes to Uphold One Accelerated Drug Approval, and Overturn Another in Treatment of Advanced Liver Cancer

May 4th 2021, 3:00pm


Members of an FDA committee recently voted in favor of upholding Keytruda’s accelerated approval indication for the treatment of patients with advanced hepatocellular carcinoma who had previously received treatment with Nexavar. However, the committee narrowly voted against maintaining Opdivo’s accelerated approval in the same patient population.

Tag Teaming Liver Cancer Care

April 30th 2021, 9:00pm


As part of the “Speaking Out” video series, CURE® spoke with Dr. Laura M. Kulik about the basics of liver cancer, highlighting the need for a multidisciplinary approach to care.

CURE’s Clinical Trial Corner: April 2021

April 29th 2021, 1:00pm


Here is a list of some recent trials that launched within the cancer space in April.

MET Inhibitor May Be Effective in Treating Patients With Hepatocellular Carcinoma With MET Overexpression Who Were Not Successful With Nexavar

April 13th 2021, 3:00pm


A 500 mg dose of Tepmetko, a MET inhibitor, in patients with hepatocellular carcinoma who were previously treated with Nexavar led to a 12-week progression-free survival rate of 63.3%.

Raising Awareness Around Liver Cancer and Disease

April 9th 2021, 6:00pm


CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.

FDA Approves Radiation Therapy for Outpatient Setting in Liver Cancer Subtype

March 19th 2021, 9:00pm


Patients with this liver cancer subtype do not need to be hospitalized to receive this treatment and, according to the agent’s manufacturer, Boston Scientific, can typically receive the therapy in approximately an hour during an outpatient procedure.

Genomic Testing Offers New Therapy Options for Hepatobiliary Cancers

March 17th 2021, 6:00pm


Genomic testing has allowed patients to receive more specific drugs that target mutations in their tumors.

Adjuvant Radiotherapy Shows Survival Benefit for Patients Who Had Resection for Distal Cholangiocarcinoma

February 25th 2021, 10:00pm


Following resection with radiotherapy increased survival rates for patients compared with those who did not receive the additional treatment.

Cholangiocarcinoma: Understanding Potential Paths For Treatment

January 27th 2021, 7:00pm


There are multiple treatment patients for patients with cholangiocarcinoma, here's what you need to know about them.